SRDX (Surmodics) Total Equity: $111.3 Mil (As of Jun. 2025)


SRDX Surmodics Inc SRDX
51 GF Score
Price $42.98
GF Value $32.10
! 5 Warning Signs
View Full Analysis

What is Surmodics Total Equity?

Surmodics SRDX -0.01% 51 Total Equity is $111.3 Mil as of Jun. 2025. GuruFocus rates SRDX with a GF Score™ of 51/100 and a GF Value™ of $32.10. The stock has 5 warning signs investors should review.

Surmodics's total equity for the quarter that ended in Jun. 2025 was $111.3 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Surmodics Total Equity Historical Data

* Premium members only.

The historical data trend for Surmodics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics Total Equity Chart

Surmodics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.06 140.09 108.39 119.91 118.90

Surmodics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.14 118.90 111.77 110.25 111.31
SRDX
51GF Score
Surmodics Inc SRDX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surmodics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Surmodics's Total Equity for the fiscal year that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=178.562-59.665
=118.9

Surmodics's Total Equity for the quarter that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=169.822-58.513
=111.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $111.3 Mil mean?
Surmodics (SRDX) has a Total Equity of $111.3 Mil as of Jun. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Surmodics and its competitors.
Is Surmodics' Total Equity too high?
Surmodics' current Total Equity is $111.3 Mil. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' Total Equity compare to CBLL and OFIX?
Surmodics' Total Equity of $111.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Surmodics and its competitors. Surmodics's current Total Equity is $111.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (SRDX) has a current Total Equity of $111.3 Mil. The stock's GF Value™ is $32.10, compared to a current price of $42.98 — trading 33.9% above its estimated fair value. The current Total Equity is $111.3 Mil. Surmodics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Surmodics (SRDX), the current Total Equity is $111.3 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Surmodics (SRDX) Overvalued in 2026?

Based on GuruFocus' analysis, Surmodics stock appears to be overvalued. The current stock price of $42.98 is trading 33.9% above its estimated GF Value™ of $32.10.

Key valuation signals for SRDX:

  • Total Equity: $111.3 Mil
  • GF Value™: $32.10 vs. price of $42.98 (33.9% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the SRDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Surmodics Business Description

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score

Get the complete analysis for SRDX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.98
Price
$32.10
GF Value